Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy

Chippaux, J. P.; Boyer, L. V.; Alagon, A.

Name:

s40409-015-0003-1.pdf

Size:

411.3Kb

Format:

PDF

Download

Author

Chippaux, J. P.
Boyer, L. V.
Alagon, A.

Affiliation

UMR 216, Mother and Child Facing Tropical Disease, Research Institute for Development (IRD), Cotonou, Benin, and School of Pharmacy, Paris Descartes University
Venom Immunochemistry, Pharmacology and Emergency Response (VIPER) Institue, University of Arizona
Institute of Biotechnology, National Autonomous University of Mexico (UNAM)
Institut de Recherche pour le Développement (IRD)

Issue Date

2015

Citation

Chippaux et al. Journal of Venomous Animals and Toxins including Tropical Diseases (2015) 21:3 DOI 10.1186/s40409-015-0003-1

Journal

Journal of Venomous Animals and Toxins including Tropical Diseases

Rights

Collection Information

This item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.

Abstract

BACKGROUND: Better treatments are urgently needed for the management of Ebola virus epidemics in Equatorial Africa. METHODS: We conducted a systematic review of the literature on the use of passive immunotherapy for the treatment or prevention of Ebola virus disease. We placed findings from this review into the context of passive immunotherapy currently used for venom-induced disease, and recent improvements in manufacturing of polyvalent antivenom products. RESULTS: Passive immunotherapy appears to be one of the most promising specific treatments for Ebola. However, its potential has been incompletely evaluated, considering the overall experience and recent improvement of immunotherapy. Development and use of heterologous serum derivatives could protect people exposed to Ebola viruses with reasonable cost and logistics. CONCLUSION: Hyperimmune equine IgG fragments and purified polyclonal whole IgG deserve further consideration as treatment for exposure to the Ebola virus.

EISSN

1678-9199

PubMed ID

25705218

PubMed Central ID

PMC4336475

DOI

10.1186/s40409-015-0003-1 [doi]

Version

Final published version

Additional Links

http://www.jvat.org/content/21/1/3

Collections

UA Faculty Publications

© 2015 Chippaux et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0).

Except where otherwise noted, this item's license is described as © 2015 Chippaux et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0).